PATENT CLAIM ANALYSIS

Application Number: 16327372
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "001890"]

Abstract:
Radiofluorinated carboximidamides are disclosed as selective IDO enzyme radioligands and generate specific binding in accordance with IDO expression in vitro. MicroPET experiments indicate [ 18 F]IDO49 specifically accumulate in IDO-expressing tumors which confirmed by Western blot and IHC analysis supported. Using Hela tumor bearing models with IFN-γ treatment confirmed that [ 18 F]IDO49 accumulation in the IFN-γ treatment tumor mouse. These results can have implications that [ 18 F]IDO49 has substantial potential as an imaging agent that targets IDO in tumors.

Claim (Index 7):
The compound of  claim 1 , wherein R 1  is C 1 -C 8  alkyl substituted with a radiolabeled isotope.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 99.0
- Lexical Diversity: 1.46774
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13070069', '13050143', '11641284', '15564666', '13780510']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7280444870236402
- 35 USC 102 Novelty (BERT): 0.5171152480230513
- Combined Prediction Score: 0.7069515631235813
- Mean Citation Score: 288.155004
- Max Citation Score: 295.71445
- Similarity Product: 200.7423687609106

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test